FOLH1 and prostate carcinoma: Moreover, recent scientific advances have also led to promising results using PSMA ligands radiolabeled with 177Lutetium (177Lu) for therapeutic purposes in advanced-stage prostate cancer patients with encouraging results [9,10,11,12].